Alexander R Mccampbell

20130115227, May 9, 2013

Jul 13, 2011

13/809475

Renee C. Gaspar - Souderton PA, US
Paul J. Shughrue - West Chester PA, US
Fubao Wang - Dresher PA, US
Weirong Wang - Harleysville PA, US
Ningyan Zhang - Ambler PA, US
Wei-Qin Zhao - North Wales PA, US
Min Xu - Ambler PA, US
Alexander McCampbell - Chalfont PA, US

C07K 16/18

4241721, 5303891, 5303882, 435375, 435 71, 506 9, 435 792

Disclosed are antibodies that bind amyloid beta-derived diffusible ligands, also known as ADDLs. The antibodies are selective for ADDLs, can penetrate the brain, and are useful in methods of detecting ADDLs and diagnosing Alzheimer's disease. The antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with ADDLs.

20130052670, Feb 28, 2013

Jul 9, 2012

13/544554

Mary Savage - West Point PA, US
Paul Shughrue - West Chester PA, US
Abigail Wolfe - Ambler PA, US
Alexander McCampbell - Chalfont PA, US

MERCK - Rahway NJ

G01N 33/566
G01N 21/64

435 794, 436501

The invention herein is directed to a selective Aβ oligomer immunoassay capable of reliably and sensitively detecting Aβ oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-AP oligomer antibodies, 19.3 and 82E1, to detect and quantify Aβ oligomers in a cerebrospinal fluid (CSF) sample. The inventive assay can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and/or to stratify AD patients according to the severity of their disease. The inventive assay can also be used as a target engagement assay that can measure bound Aβ oligomers as a surrogate end-point for the assessment of therapeutic efficacy and/or target engagement.

20220280548, Sep 8, 2022

Aug 14, 2020

17/635363

- Cambridge MA, US
Alexander McCampbell - Andover MA, US

Biogen MA Inc. - Cambridge MA

A61K 31/7125
A61K 48/00
A61P 21/00
C12N 15/113

Aspects of the application relate to compositions and methods for treating spinal muscular atrophy in a subject. In particular, this application provides therapeutic combinations of a small molecule that promotes SMN function and/or a recombinant nucleic acid that encodes the survival of motor neuron 1 (SMN1) protein (e.g., in a viral vector), and/or an antisense oligonucleotide (ASO) that increases full-length survival of motor neuron 2 (SMN2) mRNA (e.g., that is targeted to a nucleic acid molecule encoding the survival of motor neuron 2 (SMN2) and promotes the inclusion of exon 7 in SMN2 mRNA).

20230107651, Apr 6, 2023

Aug 15, 2022

17/819742

- Cambridge MA, US
John Staropoli - Boston MA, US
Guolin Zhao - Arlington MA, US
Alexander McCampbell - Andover MA, US
Christopher Cody Stebbins - Newton Highlands MA, US

Biogen MA Inc. - Cambridge MA

G01N 33/68
C12N 15/113

Featured are biornarkers for, e.g., diagnosis and prognosis of spinal muscular atrophy (SMA) as well as identification of responders to treatment of SMA. Also provided are methods of treating subjects with SMA.

20210308281, Oct 7, 2021

Aug 15, 2019

17/268390

- Cambridge MA, US
Alexander McCampbell - Andover MA, US

Biogen MA Inc. - Cambridge MA

A61K 48/00
C12N 15/113
A61P 21/00

Aspects of the application relate to compositions and methods for treating spinal muscular atrophy in a subject. In particular, this application provides therapeutic combinations of a recombinant nucleic acid that encodes the survival of motor neuron 1 (SMN1) protein (e.g., in a viral vector), and an antisense oligonucleotide (ASO) that increases full-length survival of motor neuron 2 (SMN2) mRNA (e.g., that is targeted to a nucleic acid molecule encoding the survival of motor neuron 2 (SMN2) and that promotes the inclusion of exon 7 in SMN2 mRNA).

20210041459, Feb 11, 2021

Jan 25, 2019

16/963914

- Cambridge MA, US
John Staropoli - Boston MA, US
Guolin Zhao - Arlington MA, US
Alexander McCampbell - Andover MA, US
Christopher Cody Stebbins - Newton Highlands MA, US

G01N 33/68
C12N 15/113

Featured are biomarkers for, e.g., diagnosis and prognosis of spinal muscular atrophy (SMA) as well as identification of responders to treatment of SMA. Also provided are methods of treating subjects with SMA.

20150260731, Sep 17, 2015

Jun 3, 2015

14/729343

- Livermore CA, US
- Kenilworth NJ, US
Alexander McCampbell - West Point PA, US
Mary J. Savage - West Point PA, US
Paul J. Shughrue - West Point PA, US
Fubao Wang - West Point PA, US
Weirong Wang - West Point PA, US
Abigail L. Wolfe - West Point PA, US
Wei-Qin Zhao - West Point PA, US

G01N 33/68
C07K 16/18

This invention is a selective Aβ oligomer kit and immunoassay method capable of reliably and sensitively detecting Aβ oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-Aβ oligomer antibodies, as capture and detection antibodies, to detect and quantify Aβ oligomers. The method can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and/or to stratify AD patients according to the severity of their disease.

20150023952, Jan 22, 2015

Jul 9, 2014

14/326974

- Rahway NJ, US
Paul J. Shughrue - West Chester PA, US
Fubao Wang - Dresher PA, US
Weirong Wang - Harleysville PA, US
Ningyan Zhang - Ambler PA, US
Wei-Qin Zhao - North Wales PA, US
Min Xu - Ambler PA, US
Alexander McCampbell - Chalfont PA, US

C07K 16/18

4241331, 5303873

The present invention relates to antibodies that bind amyloid β-derived diffusible ligands, also known as ADDLs. The antibodies of the invention are selective for ADDLs, can penetrate the brain, and are useful in methods of detecting ADDLs and diagnosing Alzheimer's disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with ADDLs.